Redhill Biopharma Ltd. (RDHL) SEC Filing 6-K Foreign Issuer Report for the period ending Tuesday, March 1, 2022

Redhill Biopharma Ltd.

CIK: 1553846 Ticker: RDHL

View differences made from one to another to evaluate Redhill Biopharma Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Redhill Biopharma Ltd..


Assess how Redhill Biopharma Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Redhill Biopharma Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Material Contracts, Statements, Certifications & more

Redhill Biopharma Ltd. provided additional information to their SEC Filing as exhibits

Ticker: RDHL
CIK: 1553846
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001178913-22-000875
Submitted to the SEC: Tue Mar 01 2022 9:03:04 AM EST
Accepted by the SEC: Tue Mar 01 2022
Period: Tuesday, March 1, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: